Latest Conference Articles

January 22nd 2022, 7:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

January 22nd 2022, 6:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

January 22nd 2022, 6:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.

January 22nd 2022, 5:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

January 22nd 2022, 5:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.

January 22nd 2022, 3:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

January 22nd 2022, 3:54pm

Gastrointestinal Cancers Symposium (ASCO GI)

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

January 22nd 2022, 3:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

January 21st 2022, 10:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.

January 21st 2022, 10:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.

January 21st 2022, 10:46pm

Gastrointestinal Cancers Symposium (ASCO GI)

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer.

January 21st 2022, 9:44pm

Gastrointestinal Cancers Symposium (ASCO GI)

Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.

January 21st 2022, 9:20pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.

January 21st 2022, 8:40pm

Gastrointestinal Cancers Symposium (ASCO GI)

Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.

January 21st 2022, 8:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.

January 21st 2022, 6:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.

January 20th 2022, 11:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.

January 20th 2022, 11:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events in patients with advanced gastric cancer who are receiving single-agent nivolumab.

January 20th 2022, 10:11pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited a pathologic complete response rate of 59% in patients with resectable microsatellite instable or mismatch repair deficient oeso-gastric junction adenocarcinoma.

January 20th 2022, 9:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.